

References

- Adamson, S. J., Kay-Lambkin, F. J., Baker, A. L., Lewin, T. J., Thornton, L., Kelly, B. J., & Sellman, J. D. (2010). An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). *Drug and alcohol dependence*, 110(1-2), 137–143. <https://doi.org/10.1016/j.drugalcdep.2010.02.017>
- Addolorato, G., Mirijello, A., Barrio, P., & Gual, A. (2016). Treatment of alcohol use disorders in patients with alcoholic liver disease. *Journal of Hepatology*, 65(3), 618-630.
- Afshar M, Knapp CM, Sarid-Segal O, Devine E, Colaneri LS, Tozier L, et al. (2012). The efficacy of mirtazapine in the treatment of cocaine dependence JGIM Chan et al: Pharmacotherapy for Cocaine Use Disorder 2871 with comorbid depression. *Am J Drug Alcohol Abuse*, 38(2), 181–6. doi: <https://doi.org/10.3109/00952990.2011.644002>
- Agabio R. (2005). Thiamine administration in alcohol-dependent patients. *Alcohol and Alcoholism*, 40(2), 155-6. <https://doi.org/10.1093/alcalc/agh106>
- Amato, L., Minozzi, S. & Davoli, M. (2011). Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. *Cochrane Database of Systematic Reviews*, 6(CD008537) doi: 10.1002/14651858.CD008537.pub2.
- Amato L, Minozzi S, Vecchi S, et al. (2010) Benzodiazepines for alcohol withdrawal. *Cochrane Database System Review*. 17.
- American Society of Addiction Medicine. (2020). Clinical Practice Guideline on Alcohol Withdrawal Management. https://www.asam.org/docs/default-source/quality-science/the_asam_clinical_practice_guideline_on_alcohol-1.pdf
- Anton, R.F., Latham, P., & Voronin, K. (2020). Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms. A randomized clinical trial. *JAMA Internal Medicine*. 180(5): 728-736. Doi: 10.1001/jamainternmed.2020.0249.
- American Society of Addiction Medicine. (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. *Journal of Addiction Medicine*, 14(2S), 1-91.
- Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, et al. (2011). Gabapentin combined with naltrexone for the treatment of alcohol dependence. *The American Journal of Psychiatry*. 168(7):709-17.
- Bonnet, U., Banger, M., Leweke, F. M., Maschke, M., Kowalski, T., Gastpar, M. (1999). Treatment of alcohol withdrawal syndrome with gabapentin. *Pharmacopsychiatry*. 32. Retrieved from: https://www.researchgate.net/profile/Udo-Bonnet/publication/12837347_Treatment_of_Alcohol_Withdrawal_Syndrome_with_Gabapentin/links/0deec536aa902b6c9100000/Treatment-of-Alcohol-Withdrawal-Syndrome-with-Gabapentin.pdf
- Bostwick, J.M., & Lapid, M.I., (2004). False Positives on the Clinical Institute Withdrawal Assessment for Alcohol-Revised: Is This Scale Appropriate for Use in the Medically Ill? *Psychosomatics*, 45(3), 256-261.
- Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. *Addiction (Abingdon, England)*. 2004;99(7):811-28.
- Brett, J., & Murnion, B. (2015). Management of benzodiazepine misuse and dependence. *Australian prescriber*, 38(5), 152–155. <https://doi.org/10.18773/austprescr.2015.055>
- British Columbia Centre on Substance use (BCCSU). (2019). Provincial guideline for the clinical management of high-risk drinking and alcohol use disorder. Retrieved from: <https://crismprairies.ca/wp-content/uploads/2020/01/AUD-Guideline.pdf>

- Budney, A. J., Novy, P. L., & Hughes, J. R. (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence. *Addiction*, 94(9), 1311-1322.
- Budney, A. J., Moore, B. A., Vandrey, R. G., & Hughes, J. R. (2003). The time course and significance of cannabis withdrawal. *Journal of Abnormal Psychology*, 112(3), 393-402.
- Canadian Coalition for Seniors Mental Health. (2019). Canadian Guidelines on Alcohol Use Disorder Among Older Adults. Retrieved from: https://ccsmh.ca/wp-content/uploads/2019/12/Final_Alcohol_Use_DisorderV6.pdf
- Carcano-calderon, L., Ramos-Penafiel, C.O., Salcedo-Roldan, M., Diaz-Estrada, I., Galvan-Flores, F., Duran-Guzman, R., Sandoval-Gutierrez, F., ..., & Collazo-Jalloma, J. (2015). Factor analysis and correlation between CIWA-Ar protocol and biochemical-hematic profile in patients with alcohol withdrawal syndrome. *Revista Medica Del Hospital General De Mexico*, 78(4), 155-161. <http://dx.doi.org/10.1016/j.hgmx.2015.06.003>
- Carnwath, T., & Hardman, J. A. (1998). Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. *Drug and Alcohol Dependence*, 50(3), 251-254.
- Centre for Addictions and Mental Health. (2021, May). Opioid agonist therapy: A synthesis of Canadian guidelines for treating opioid use disorder. Available at: www.camh.ca
- Chan, B., Kondi, K., Freeman, M., et. al. (2019). Pharmacotherapy for cocaine use disorder - A systematic review and meta-analysis. *Journal of General Internal Medicine* 34. 2858-2873. Retrieved from: <https://link.springer.com/article/10.1007/s11606-019-05074-8>
- Clarke, S., Franklyn, M., Kahan, M., Leary, T., Nikodem, P. (2019) Clinical best practices in addiction medicine: A guide for RAAM clinicians. Mentoring, education, and clinical tools for addiction: primary-care-hospital integration. Available at: <http://www.metaphi.ca>
- Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. Geneva: World Health Organization; 2009. 4, Withdrawal Management. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK310652/>
- Clemency, B. M., Eggleston, W., Shaw, E. W., et al., (2019). Hospital observation upon reversal (HOUR) with naloxone: A prospective clinical prediction rule validation study. *Academic Emergency Medicine* 26(1). 7-15. Doi 10.1111/acem.13567
- Conner, J., Daniel, S., Le Foll, B., Hoch, E., Budney, A.J., & Hall, W. (2021). Cannabis use and cannabis use disorder. *Nature Publishing Group*. 7(1).
- COVID-19: Alcohol withdrawal management protocol. (2020). Mentoring, Education and Clinical Tools in Addictions: Partners in Health Integration. Available at: <http://www.metaphi.ca>
- Crowther, R., & Lum, H. (2017). Alcohol withdrawal education resource. University Health Network.
- Dervaux, A., & Laqueille, X. (2017). Le traitement par thiamine (vitamine B1) dans l'alcoolodépendance [Thiamine (vitamin B1) treatment in patients with alcohol dependence]. *Presse medicale* (Paris, France : 1983), 46(2 Pt 1), 165-171. <https://doi.org/10.1016/j.lpm.2016.07.025>
- Drug & Alcohol Services South Australia (DASSA). (2017). Management of patients presenting with acute methamphetamine-related problems: evidence summary. Retrieved from: <https://www.sahealth.sa.gov.au/wps/wcm/connect/915c4c60-a766-414c-8606-94d1702d052f/Management+of+meth+presentations++evidence+summary+2017+final.pdf?MOD=AJPERES&ACHEID=ROOTWORKSPACE-915c4c60-a766-414c-8606-94d1702d052f-nwLRZXO>

- ED Screening of Alcohol Withdrawal Outpatient Management; Clinical Guidelines, Suggested Template/Order Set, Decision Flow. Health Plan of California. http://www.partnershiphp.org/Providers/HealthServices/Documents/First%20Do%20No%20Harm_ED%20screening%20for%20entry%20into%20outpatient%20rehab%20program%20%20Final_COM.pdf
- Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J. & Room, R. (2017). Lower-Risk Cannabis Use Guidelines (LRCUG): An evidence-based update. *American Journal of Public Health*, 107 (8). DOI: 10.2105/AJPH.2017.303818.
- Fluyau, D., Mitra, P., Lorthe, K. (2019). Antipsychotics for amphetamine psychosis. A systematic review. *Frontiers in Psychiatry*. 10. doi: 10.3389/fpsyt.2019.00740
- Furieri FA, Nakamura-Palacios EM. (2007). Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. *The Journal of Clinical Psychiatry*, 68(11), 1691-700.
- Gerra, G., Zaimovic, A., Giusti, F., Di Gennaro, C., Zambelli, U., Gardini, S., & Delsignore, R. (2001). Lofexidine versus clonidine in rapid opiate detoxification. *Journal of substance abuse treatment*, 21(1), 11-17.
- Gray, S., Borgundvaag, B., Srivastava, A., Kahan, M. (2010). Feasibility and reliability of the SHOT: A short scale for measuring pretreatment severity of alcohol withdrawal in the emergency department. *Academic Emergency Medicine*.
<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1553-2712.2010.00885.x>
- Glasner-Edwards, S., & Mooney, L. (2016). Methamphetamine psychosis: Epidemiology and management. *CNS Drugs*. 28(12), 1115-1126. Doi: 10.1007/s40263-014-0209-8.
- Gulbranson, K., Lemay, G., & Molnar, F. J. (2017). De-prescribing benzodiazepines in the elderly: a review. *Can Geriatri Soc J CME*, 7(1).
- Haber, P., Linterzis, D., Proude, E., Lopato, O. 2009. Guidelines for the treatment of alcohol problems. Australian government department of health and aging. Available at:
https://www.health.gov.au/sites/default/files/guidelines-for-the-treatment-of-alcohol-problems_0.pdf.
[Accessed June 2009].
- Haile, C. N., & Kosten, T. R. (2013). Pharmacotherapy for stimulant-related disorders. *Current psychiatry reports*, 15(11), 415.
<https://doi.org/10.1007/s11920-013-0415-y>
- Hamilton, J. D., Nguyen, Q.X., & Rubio, N.B. (2009). Olanzapine in cocaine dependence: A doubleblind, placebo-controlled trial. *American Journal on Addictions*. 18. 48-52.
- Indave BI, Minozzi S, Pani PP, Amato L. (2016). Antipsychotic medications for cocaine dependence. *Cochrane Database Syst Rev*, 3, Cd006306. pmid:26992929
- Johnson BA, Ait-Daoud N, Wang X-Q, Penberthy JK, Javors MA, Seneviratne C, et al. (2013). Topiramate for the treatment of cocaine addiction: a randomized clinical trial. *JAMA Psychiatry*, 70(12), 1338–46. doi: <https://doi.org/10.1001/jamapsychiatry.2013.2295>
- Kattimani S, Bharadwaj B. (2013). Clinical management of alcohol withdrawal: A systematic review. *Industrial Psychiatry Journal*, 22(2), 100-8. doi: 10.4103/0972-6748.132914. PMID: 25013309; PMCID: PMC4085800.
- Kahn, A., Mumford, J. P., Rogers, G. A., & Beckford, H. (1997). Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. *Drug and alcohol dependence*, 44(1), 57-61.
- Kah-Seong Loke (2016). Amphetamines: A complex care approach. VDDI Statewide Forum, 25, October, the Treacy Centre, Parkville. Received from: <http://www.dualdiagnosis.org.au/home/images/documents/8.+Amphetamines.+A+complex+care+approach.pdf>
- Kalk, N.J. & Lingford-Hughes, A.R. (2014). The clinical pharmacology of acamprosate. *The British Journal of Clinical Pharmacology*. 77(2): 315-32.

- Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O'Brien CP. (2013). A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. *Drug Alcohol Depend*, 133(1), 94–9. doi: <https://doi.org/10.1016/j.drugalcdep.2013.05.026>
- Kishi T, Matsuda Y, Iwata N, Correll CU. (2013). Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. *J Clin Psychiatry*, 74(12), e1169–80. PMID:24434105
- Kondo, K., Morasco, B.J., Nugent, S., Ayers, C., O'Neil, M.E., Freeman, M., Paynter, R., & Kansagara, D. (2020). Pharmacotherapy for the treatment of cannabis use disorder: A systematic review. Department of Veterans Affairs (US), Washington (DC).
- Korczak, V., Kirby, A., & Gunja, N. (2016). Chemical agents for the sedation of agitated patients in the ED: A systematic review. *The Journal of Emergency Medicine*. 34(12). 2426-2431. doi: 10.1016/j.ajem.2016.09.025.
- Kuzmaul, A. K., Palmer, E. C., & Frederick, E. K. (2020). Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: a systematic review. *Journal of the American Pharmacists Association*, 60(1), 145-152.
- LaMarre, A. (2014). Literature review on withdrawal management. Guelph, ON: Institute for Community Engaged Scholarship. <https://atrium.lib.uoguelph.ca/xmlui/handle/10214/8902>
- Leelahanaj T, Kongsakon R, Netrakom P. (2005). A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. *J Med Assoc Thai*, 88(Suppl 3), S43–52.
- Leggio, L., & Lee, M. R. (2017). Treatment of alcohol use disorder in patients with alcoholic liver disease. *The American Journal of Medicine*, 130(2), 124-134.
- Leung, J. G., Hall-Flavin, D., Nelson, S., Schmidt, K. A., Schak, K. M. (2015). The role of gabapentin in the management of alcohol withdrawal and dependence. *Annals of Pharmacotherapy*. doi: 10.1177/1060028015585849.
- Lin, S. K., Strang, J., Su, L. W., Tsai, C. J., & Hu, W. H. (1997). Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. *Drug and alcohol dependence*, 48(2), 127-133.
- Manasco, A., Chang, S., Larriviere, J., Hamm, L. L., Glass, M. (2012). Alcohol withdrawal. *Southern Medical Journal*. 105. https://loyolamedicine.org/sites/default/files/gme/internal-medicine/general-medicine/reading-list/alcohol_withdrawal_2012.pdf
- Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. (2014). Gabapentin treatment for alcohol dependence: a randomized clinical trial. *JAMA Internal Medicine*, 174(1), 70-7.
- Mong, J., Ahamad, K., & Bach, P. (2021). Anticraving medication for moderate to severe alcohol use disorder. *CMAJ*, 193(19), E695-E695.
- Muncie, H. L., Yasinian, Y., & Oge, L. (2013). Outpatient management of alcohol withdrawal syndrome. *American Family Physician*, 88(9), 589-595. <https://www.aafp.org/afp/2013/1101/afp20131101p589.pdf>
- Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, et al. (2009). A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. *Alcoholism, clinical and experimental research*, 33(9), 1582-8.
- National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis and management of physical complications. Clinical guideline [CG115] 23 February 2010. <https://www.nice.org.uk/guidance/cg115>
- Oliveto, A., Poling, J., Mancino, M. J., Feldman, Z., Cubells, J. F., Pruzinsky, R., ... & Kosten, T. R. (2011). Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. *Drug and alcohol dependence*, 113(2-3), 184-191. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/20828943/>

- Ontario Provincial Standards for Withdrawal Management Services. (2014). Addictions and Mental Health Ontario. <https://www.st-leonards.com/sites/default/files/uploads/files/2014WMSStandards.pdf>
- Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. (2010). Disulfiram for the treatment of cocaine dependence. *Cochrane Database Syst Rev*, Cd007024. pmid:20091613
- Parsons B, Tive L, Huang S. (2004). Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. *The American Journal of Geriatric Pharmacotherapy*, 2(3), 157-62
- Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. (2006). Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. *Arch Gen Psychiatry*, 63(2), 219–28. doi: <https://doi.org/10.1001/archpsyc.63.2.219>
- Pottie, K., Thompson, W., Davies, S., Grenier, J., Sadowski, C. A., Welch, V., ... & Farrell, B. (2018). Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. *Canadian Family Physician*, 64(5), 339-351.
- Pribek, I., Kovacs, I., Kadar, B.K., Kovacs, C.S., Richman, M.J., Janka, Z., Ando, B., & Lazar, B.A. (2021). Evaluation of the course and treatment of Alcohol Withdrawal Syndrome with the Clinical Institute Withdrawal Assessment for Alcohol – Revised: A systematic review-based meta-analysis. *Drug and Alcohol Dependence*. <https://doi.org/10.1016/j.drugalcdep.2021.108536>
- Raymond F. Anton, M. D. Latham, P., Voronin, M. D. et. al. (2020, May 1). Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms. *JAMA Internal Medicine*. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2762700>
- Richards, J. R., & Laurin, E. G. (2020). Methamphetamine toxicity. *StatPearls*. Retrieved from: <https://www.ncbi.nlm.nih.gov/books/NBK430895/>
- Sevarino, K., Saxon, A. J., & Hermann, R. (2018). Medically supervised opioid withdrawal during treatment for addiction. UpToDate [Internet]. Waltham (MA): UpToDate
- Singh M, Keer D, Klimas J, Wood E, Werb D. (2016). Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. *Addiction*, 111(8), 1337–46. doi: <https://doi.org/10.1111/add.13328>
- Sobell, L. C., Kwan, E., & Sobell, M. B. (1995). Reliability of a drug history questionnaire (DHQ). *Addictive behaviors*, 20(2), 233–241. [https://doi.org/10.1016/0306-4603\(94\)00071-9](https://doi.org/10.1016/0306-4603(94)00071-9)
- Spiegel, D., Kumari, N., & Petri, J. (Oct 2012). Safer use of benzodiazepines for alcohol detoxification. *Current Psychiatry*, 11(10), 10–15.
- Srivastava, A. B., Mariani, J. J., & Levin, F. R. (2020). New directions in the treatment of opioid withdrawal. *The Lancet*, 395(10241), 1938-1948.
- Thom, R.P., Levy-Carrick, N.C., Phil, M., Bui, M., & Silbersweig, D. (2019). Delirium. *The American Journal of Psychiatry*. <https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2018.18070893>
- Thomson AD, Cook CC, Touquet R, Henry JA, Royal College of Physicians, London. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and Emergency Department [published correction appears in *Alcohol Alcohol*. 2003 38:291]. *Alcohol Alcohol*. 2002;37:513–21.
- Trivedi, M.H., Walker, R., Ling, W. et al., (2021). Bupropion and Naltrexone in Methamphetamine Use Disorder. *The New England Journal of Medicine*. 384:2.

- Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. (2014). Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. *Drug Alcohol Depend*, 140, 92–100. doi: <https://doi.org/10.1016/j.drugalcdep.2014.03.033>
- United Nations Office of Drugs and Crime, TREATMENT OF STIMULANT USE DISORDERS: CURRENT PRACTICES AND PROMISING PERSPECTIVES DISCUSSION PAPER. https://www.unodc.org/documents/drug-prevention-and-treatment/Treatment_of_PSUD_for_website_24.05.19.pdf
- Verachai, V., Rukngan, W., Chawanakrasaesin, K., et al. (2014). Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. *Psychopharmacology*. 231: 3099-3108. Doi: 10.1007/s00213-014-3485-6.
- Vissers, F. H., Knipschild, P. G., & Crebolder, H. F. (2007). Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. *Pharmacy World & Science*, 29(6), 641-646.
- Voshaar, R. C. O., Gorgels, W. J., Mol, A. J., Van Balkom, A. J., Van De Lisdonk, E. H., Breteler, M. H., ... & Zitman, F. G. (2003). Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. *The British Journal of Psychiatry*, 182(6), 498-504.
- Walsh, S. L., Strain, E. C., & Bigelow, G. E. (2003). Evaluation of the effects of lofexidine and clonidine on naloxone precipitated withdrawal in opioid dependent humans. *Addiction*, 98(4), 427-439.
- Weresch, J., Kirkwood, J., & Korownyk, C. S. (2021). Gabapentin for alcohol use disorder. *Canadian Family Physician*. 67(4). 269. Doi: <http://doi.org/10.46747/cfp.6704269>
- WHO. (2009). Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. <https://www.ncbi.nlm.nih.gov/books/NBK310654/>
- William, M. W., Liss, D. B., Schwarz, E. S., Mullins, M. E. (2017). Do heroin overdose patients require observation after receiving naloxone? *Clinical Toxicology*. 55(2). 81-87. doi: 10.1080/15563650.2016.1253846.
- Xavier, A. S., Behera, S. K., & Selvarajan, S. (2020). An overview on medication-assisted treatment (MAT) for opioid dependence. *Journal of Opioid Management*, 16(2), 142.
- Xiong, G. L. (2018). Wernicke-Korsak syndrome treatment and management. *Drug and Diseases*. <https://emedicine.medscape.com/article/288379-treatment>
- Zun LS. Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy. *J Emerg Med*. 2018 Mar;54(3): 364-374. Retrieved from: <https://isiarticles.com/bundles/Article/pre/pdf/116992.pdf>